Satovsky Asset Management LLC acquired a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,075 shares of the company’s stock, valued at approximately $607,000. Establishment Labs makes up approximately 0.1% of Satovsky Asset Management LLC’s investment portfolio, making the stock its 26th largest position.
Several other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Establishment Labs in the 2nd quarter valued at approximately $135,752,000. William Blair Investment Management LLC purchased a new position in Establishment Labs during the second quarter worth $61,273,000. Rice Hall James & Associates LLC purchased a new position in Establishment Labs during the second quarter worth $48,134,000. Goldman Sachs Group Inc. raised its holdings in shares of Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares during the last quarter. Finally, Viking Global Investors LP acquired a new position in shares of Establishment Labs in the second quarter worth $14,669,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.
Establishment Labs Stock Performance
Shares of ESTA opened at $72.67 on Monday. Establishment Labs Holdings Inc. has a fifty-two week low of $36.53 and a fifty-two week high of $97.59. The company has a market capitalization of $2.17 billion, a PE ratio of -55.47 and a beta of 1.07. The stock has a fifty day moving average of $86.19 and a two-hundred day moving average of $74.86. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84.
Analyst Ratings Changes
A number of analysts recently commented on the company. Needham & Company LLC increased their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. BTIG Research upped their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus price target of $100.25.
Get Our Latest Stock Report on Establishment Labs
Establishment Labs Company Profile
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Further Reading
- Five stocks we like better than Establishment Labs
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
